Kiniksa Pharmaceuticals International(KNSA.US) Officer Sells US$3.49 Million in Common Stock
Kiniksa Pharmaceuticals International | 10-Q: Quarterly report
Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates
There's No Escaping Kiniksa Pharmaceuticals International, Plc's (NASDAQ:KNSA) Muted Revenues Despite A 41% Share Price Rise
Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30
Express News | Kiniksa Pharmaceuticals Ltd. : Wells Fargo Raises Target Price to $35 From $34
Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35
Earnings Call Summary | Kiniksa Pharmaceuticals International(KNSA.US) Q2 2024 Earnings Conference
Form 144 | Kiniksa Pharmaceuticals International(KNSA.US) Officer Proposes to Sell 3.49 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 23, $Kiniksa Pharmaceuticals International(KNSA.US)$ Officer Patel Sanj K intends to sell 136.12K shares of its common stock on Jul 23, with a total market value of
Kiniksa Pharmaceuticals International, Plc (KNSA) Q2 2024 Earnings Call Transcript
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $34
Kiniksa Pharmaceuticals Analyst Ratings
Express News | Kiniksa Pharmaceuticals up 26.5% to Over Four-Yr High After Co Beats Q2 Revenue Estimates
Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating
Express News | Kiniksa Pharmaceuticals Ltd : Wedbush Raises Target Price to $34 From $30
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Express News | Kiniksa Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results and Raised Its FY24 Net Product Revenue Guidance
Express News | Kiniksa Expects 2024 Arcalyst Net Product Revenue Of $405M-$415M, Compared To Prior Guidance Of Between $370M-$390M, The Company Expects To Remain Cash Flow Positive On An Annual Basis